<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01076517</url>
  </required_header>
  <id_info>
    <org_study_id>XHEP0016-NOT-RESEARCH</org_study_id>
    <secondary_id>HEP0016</secondary_id>
    <secondary_id>14324</secondary_id>
    <nct_id>NCT01076517</nct_id>
  </id_info>
  <brief_title>A Humanitarian Device Exemption Treatment Protocol of TheraSphere For Treatment of Unresectable Hepatocellular Carcinoma</brief_title>
  <official_title>A Humanitarian Device Exemption Treatment Protocol of TheraSphere For Treatment of Unresectable Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>BTG International Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <brief_summary>
    <textblock>
      To provide Therasphere treatment for patients diagnosed with unresectable liver cancer.
    </textblock>
  </brief_summary>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <condition>Liver Cancer</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Therasphere</intervention_name>
    <description>Beta-emitting 90yttrium encapsulated in glass microspheres for intraarterial administration to the liver.</description>
    <other_name>HCC</other_name>
    <other_name>hepatocellular carcinoma treatment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients of any age, of any race or sex, who have hepatocellular carcinoma of the liver,
        and who are able to give informed consent, will be eligible. Patients must have an ECOG
        Performance Status score of &lt;/= 2, with a life expectancy of &gt;/= 3 months, non-pregnant
        with an acceptable contraception in premenopausal women. Patients must be &gt;4 weeks since
        prior radiation or prior surgery and at least 1 month post other chemotherapy.

        Exclusion Criteria:

          -  Contraindications to angiography and selective visceral catheterization

          -  Evidence of potential delivery of greater than 16.5 mCi (30 Gy absorbed dose) of
             radiation to the lungs

          -  Evidence of any detectable Tc-99m MAA flow to the stomach or duodenum, after
             application of established angiographic techniques to stop or mitigate such flow (ex.
             placing catheter distal to gastric vessels)

          -  Significant extrahepatic disease representing an imminent life-threatening outcome

          -  Severe liver dysfunction or pulmonary insufficiency

          -  Active uncontrolled infection

          -  Significant underlying medical or psychiatric illness

          -  Pregnancy

        Patients will be excluded: if they have a co-morbid disease or an acute or chronic
        condition that would preclude safe delivery of TheraSphere treatment and place the patient
        at undue risk.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Yung-Ho Sze</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Danielle Katz</last_name>
    <phone>650-723-0728</phone>
    <email>dkatz@stanfordhealthcare.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Danielle Katz</last_name>
      <phone>650-723-0728</phone>
      <email>dkatz@stanfordhealthcare.org</email>
    </contact>
    <investigator>
      <last_name>Daniel Y Sze, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>John D Louie, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nishita Kothary, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Wang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 24, 2010</study_first_submitted>
  <study_first_submitted_qc>February 24, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2010</study_first_posted>
  <last_update_submitted>April 16, 2018</last_update_submitted>
  <last_update_submitted_qc>April 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Daniel Yung-Ho Sze</investigator_full_name>
    <investigator_title>Professor of Radiology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

